166 related articles for article (PubMed ID: 31075107)
1. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ
PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107
[TBL] [Abstract][Full Text] [Related]
2. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
[TBL] [Abstract][Full Text] [Related]
3. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
[TBL] [Abstract][Full Text] [Related]
4. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
5. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
6. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
van Rhenen A; van Dongen GA; Kelder A; Rombouts EJ; Feller N; Moshaver B; Stigter-van Walsum M; Zweegman S; Ossenkoppele GJ; Jan Schuurhuis G
Blood; 2007 Oct; 110(7):2659-66. PubMed ID: 17609428
[TBL] [Abstract][Full Text] [Related]
7. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
11. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Yalcintepe L; Frankel AE; Hogge DE
Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
[TBL] [Abstract][Full Text] [Related]
12. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
Dourado KMC; Baik J; Oliveira VKP; Beltrame M; Yamamoto A; Theuer CP; Figueiredo CAV; Verneris MR; Perlingeiro RCR
Blood; 2017 May; 129(18):2526-2536. PubMed ID: 28351936
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
14. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
Guillaume T; Dehame V; Chevallier P; Peterlin P; Garnier A; Grégoire M; Pichinuk E; Rubinstein DB; Wreschner DH
Exp Hematol; 2019 Feb; 70():97-108. PubMed ID: 30593830
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches.
Annaloro C; Onida F; Saporiti G; Lambertenghi Deliliers G
Curr Pharm Biotechnol; 2011 Feb; 12(2):217-25. PubMed ID: 21044004
[TBL] [Abstract][Full Text] [Related]
16. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
17. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
18. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Herrmann H; Kneidinger M; Cerny-Reiterer S; Rülicke T; Willmann M; Gleixner KV; Blatt K; Hörmann G; Peter B; Samorapoompichit P; Pickl W; Bharate GY; Mayerhofer M; Sperr WR; Maeda H; Valent P
Curr Cancer Drug Targets; 2012 Jan; 12(1):51-63. PubMed ID: 22165967
[TBL] [Abstract][Full Text] [Related]
19. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
[TBL] [Abstract][Full Text] [Related]
20. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
